Request Demo
Last update 23 Jan 2025
HDM-SPIRE
Last update 23 Jan 2025
Overview
Basic Info
Drug Type Prophylactic vaccine |
Synonyms Antiallergy vaccine house dust mite Circassia, House dust mite allergy immunotherapy Circassia, ToleroMune HDM |
Target- |
Mechanism Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with HDM-SPIRENCT02150343
A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis
NCT02061670
A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis
NCT02061709
A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate Three Dose Regimens of Ragweed-SPIRE in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber
100 Clinical Results associated with HDM-SPIRE
Login to view more data
100 Translational Medicine associated with HDM-SPIRE
Login to view more data
100 Patents (Medical) associated with HDM-SPIRE
Login to view more data
1
Literatures (Medical) associated with HDM-SPIRE01 Aug 2021The journal of allergy and clinical immunology. In practiceQ1 · MEDICINE
Safety and tolerability of the standardized quality house dust mite sublingual immunotherapy tablet in real life: A noninterventional, open-label study
Q1 · MEDICINE
Article
Author: Wolf, Hendrik ; Hölscher, Uwe ; Wüstenberg, Eike ; Schnitker, Jörg ; Futschik, Thomas ; Reiber, Rainer ; Schwab, Jan-Alexander
100 Deals associated with HDM-SPIRE
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Allergic rhinoconjunctivitis | Phase 2 | CA | 01 Jan 2014 | |
| Ragweed Sensitivity | Phase 2 | CA | 01 Jan 2014 | |
| Rhinitis, Allergic, Seasonal | Phase 2 | CA | 01 Jan 2014 | |
| Asthma | Phase 2 | CA | 01 Sep 2013 | |
| Anaphylaxis | Phase 2 | CA | 01 Nov 2009 | |
| House dust mite allergy | Phase 2 | CA | 01 Nov 2009 | |
| Rhinoconjunctivitis | Phase 2 | CA | 01 Nov 2009 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | HDM-SPIRE 12-nmol | nkiyzsbzcg(qhotqjvtzq) = HDM-SPIRE was well tolerated with no treatment related adverse events (AE) msjlndszeg (hmaqehwykw ) | Positive | 01 Feb 2015 | ||
Placebo |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free